Therefore, finding an accurate, non-invasive and repeatable method to assess TILs levels may help predict clinical outcomes for HER2-positive BC patients who may benefit not only from neoadjuvant or anti-HER2-targeted therapies but also from immunotherapy. This evidence concerns the gene ERBB2 and breast cancer.